Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.67 -3.7%	$0.69	$0.57 ▼ $3.00	$5.29M	1.21	1.10 million shs	282,740 shs
FNCH Finch Therapeutics Group	$13.60 +0.7%	$13.20	$0.90 ▼ $15.85	$21.84M	1.27	2,275 shs	2,136 shs
SLGL Sol-Gel Technologies	$7.22 -0.3%	$6.43	$3.34 ▼ $16.50	$20.12M	1.11	31,088 shs	1,406 shs
VOR Vor Biopharma	$0.22 -6.5%	$0.48	$0.13 ▼ $1.80	$27.38M	-0.21	1.02 million shs	1.45 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+5.38%	+0.84%	+3.82%	-7.27%	-52.03%
FNCH Finch Therapeutics Group	+0.74%	+4.62%	+6.75%	-9.93%	+1,306.37%
SLGL Sol-Gel Technologies	-0.33%	-3.61%	+902.19%	+17.54%	-8.55%
VOR Vor Biopharma	+17.21%	+32.67%	-64.58%	-73.38%	-82.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	2.8693 of 5 stars	3.8	3.0	3.1	0.0	1.3
FNCH Finch Therapeutics Group	0.9336 of 5 stars	0.0	5.0	0.6	1.7	0.6
SLGL Sol-Gel Technologies	2.1954 of 5 stars	3.5	3.0	2.3	1.7	0.0
VOR Vor Biopharma	3.7224 of 5 stars	4.2	5.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.50	Strong Buy	$8.00	1,094.03% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	454.02% Upside
VOR Vor Biopharma	2.40	Hold	$7.06	3,120.97% Upside

Current Analyst Ratings Breakdown

Latest ADIL, VOR, FNCH, and SLGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$7.00 ➝ $0.40
3/21/2025	VOR Vor Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
3/21/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.50 ➝ $13.00
3/21/2025	VOR Vor Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/20/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
FNCH Finch Therapeutics Group	$110K	198.56	N/A	N/A	$14.25 per share	0.95
SLGL Sol-Gel Technologies	$12.10M	1.66	N/A	N/A	$1.67 per share	4.32
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$1.46	N/A	N/A	N/A	N/A	-168.25%	-148.46%	8/12/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
SLGL Sol-Gel Technologies	-$27.24M	-$4.70	N/A	N/A	N/A	-81.75%	-27.17%	-22.49%	8/14/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ADIL, VOR, FNCH, and SLGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/14/2025	Q1 2025	ADIL Adial Pharmaceuticals	-$0.50	-$0.34	+$0.16	-$0.34	N/A	N/A
3/4/2025	Q4 2024	ADIL Adial Pharmaceuticals	-$0.38	-$0.15	+$0.23	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	6.78	6.78
FNCH Finch Therapeutics Group	N/A	3.87	3.87
SLGL Sol-Gel Technologies	N/A	5.81	5.81
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
FNCH Finch Therapeutics Group	21.77%
SLGL Sol-Gel Technologies	26.18%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	5.24%
FNCH Finch Therapeutics Group	44.90%
SLGL Sol-Gel Technologies	66.51%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	7.90 million	6.07 million	No Data
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
SLGL Sol-Gel Technologies	50	2.79 million	9.33 million	Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

ADIL, VOR, FNCH, and SLGL Headlines

Recent News About These Companies

Vor Bio details extent of Cambridge layoffs in state filing

June 2 at 4:07 PM | bizjournals.com

Cambridge biotech company researching blood cancers to close, lay off 155

June 2 at 4:07 PM | masslive.com

Vor Biopharma Inc. Advanced Charts - Barron's

May 29, 2025 | barrons.com

RA Capital's biotech incubator lays off staffers: Stat

May 15, 2025 | fiercebiotech.com

Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns

May 10, 2025 | investing.com

JMP Securities Downgrades Vor Biopharma (VOR)

May 10, 2025 | msn.com

Vor Biopharma draws downgrades on strategic review

May 9, 2025 | msn.com

Jones Trading cuts Vor Biopharma stock rating to Hold

May 9, 2025 | investing.com

HC Wainwright & Co. Downgrades Vor Biopharma (VOR)

May 9, 2025 | msn.com

4 more biotechs cut staff amid market tumult

May 9, 2025 | biopharmadive.com

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

May 8, 2025 | endpts.com

Vor Bio Winding Down Operations, Cutting Workforce, Exploring Potential Sale

May 8, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025 | finanznachrichten.de

Vor Biopharma stock plummets on operation wind-down

May 8, 2025 | in.investing.com

Vor Bio to wind down, halting cell therapy trials and shedding most staff

May 8, 2025 | fiercebiotech.com

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025 | globenewswire.com

Vor Biopharma Inc. (NYSE:VOR) Shares Bought by RA Capital Management L.P.

May 3, 2025 | marketbeat.com

Vor Biopharma faces Nasdaq delisting over low stock price

April 27, 2025 | investing.com

Vor Bio price target lowered to $5 from $12 at Stifel

March 22, 2025 | markets.businessinsider.com

Vor Bio price target lowered to $13 from $17.50 at H.C. Wainwright

March 22, 2025 | markets.businessinsider.com

Vor Bio files $350M mixed securities shelf

March 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
By Nathan Reiff | May 15, 2025
View Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
Retail Investors Are Betting Big on Rocket Lab—Should You Too?
By Ryan Hasson | May 16, 2025
View Retail Investors Are Betting Big on Rocket Lab—Should You Too?
Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?
By Thomas Hughes | May 22, 2025
View Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?
Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
By Nathan Reiff | May 10, 2025
View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?

ADIL, VOR, FNCH, and SLGL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.67 -0.03 (-3.68%)

As of 12:52 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Finch Therapeutics Group NASDAQ:FNCH

$13.60 +0.10 (+0.74%)

As of 06/2/2025 03:12 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Sol-Gel Technologies NASDAQ:SLGL

$7.22 -0.02 (-0.28%)

As of 10:19 AM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Vor Biopharma NYSE:VOR

$0.22 -0.02 (-6.49%)

As of 12:57 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time